https://www.selleckchem.com/products/gw4869.html
185; 95%CI, 0.059-0.582; P=0.0039). The hematoma was gradually reduced in all 46 patients and absorbed after non-surgical treatment at 3months. There was no significant difference in hematoma volume between the two groups. No serious adverse event was found. The administration of mNGF and citicoline was well-tolerated in patients with acute ICH. mNGF was associated with improved neurological function and less disability in patients with ICH. Therefore, the quality of life of patients with ICH may be improved by mNGF. The trial is registe
Like
Comment
Share
